VHI generally reimburses a new drug within a month or two of it receiving EMA approval but this is not the case with Laya or Irish Life, who await the long drawn out HSE/NCPE approval which takes around 2 years.
Agree totally with JimmyB99.sn't the reality that the core issue is the relative length of time taking to approve modern drugs in Ireland relative to other countries?
A good reason for one to go public for cancer treatment?Public patients can access these new cancer medicines once they are approved by the HSE system for reimbursement and have been approved by the European Medicines Agency.
Not the same thing, though. As the EMA indicate, it is not their remit to make a cost/benefit analysis of any new drug. They assess on the basis of clinical benefits, side effects and risks. It is the role of national authorities to make their own pharmacoeconomic assessment, based on local pricing, health budgets and health priorities.The issue is that HSE/NCPE are taking up 2 years to approve drugs that have already received FDA, EMA approval.
Or Look after you before you get ill as per advertYou misunderstand, Clubman
Effectively, once the HSE approves it, everyone has access to it. That's not the issue.
The issue, typically, is that the Irish State (via various agencies in the approval process) deems that next generation drugs are not value for money. Eventually, when pretty much every other European Country has approved such drugs in their primary tier healthcare, then (and only then!) will it become approved here. Truth is no one really gives a hoot about any of this until......you, or someone close to you, is impacted.
If you need these drugs when they first few years of their availability - you will not get them through LAYA or Irish Life and you will not get them via the public system.
Remember - if you need proven cancer drugs Laya will not look after you always. Dems the facts!
Truth is no one really gives a hoot about any of this until......you, or someone close to you, is impacted.
As a society, we ask a private terminally ill person to go public to fight the system to gain access to the most effective medication. This is pretty pathetic. I
You believe, I think, that the article refers to niche treatments for rare cancers
Nobody is arguing against such an assessment, but rather the speed with which Ireland delivers that assessment. Second worst in Europe!Novel treatments should all be subject to pharmacoeconomic assessment.
I have seen that but where does it come from? Any references?Second worst in Europe
We use cookies and similar technologies for the following purposes:
Do you accept cookies and these technologies?
We use cookies and similar technologies for the following purposes:
Do you accept cookies and these technologies?